Sfmg LLC acquired a new stake in AbbVie Inc. (NYSE:ABBV) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 4,378 shares of the company’s stock, valued at approximately $285,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of ABBV. Bollard Group LLC raised its stake in AbbVie by 0.5% in the first quarter. Bollard Group LLC now owns 3,745 shares of the company’s stock worth $244,000 after buying an additional 20 shares during the last quarter. TRUE Private Wealth Advisors raised its stake in AbbVie by 0.5% in the first quarter. TRUE Private Wealth Advisors now owns 4,787 shares of the company’s stock worth $313,000 after buying an additional 24 shares during the last quarter. Country Club Trust Company n.a. raised its stake in AbbVie by 0.6% in the first quarter. Country Club Trust Company n.a. now owns 4,434 shares of the company’s stock worth $289,000 after buying an additional 26 shares during the last quarter. Stratford Consulting LLC raised its stake in AbbVie by 0.7% in the first quarter. Stratford Consulting LLC now owns 3,959 shares of the company’s stock worth $258,000 after buying an additional 29 shares during the last quarter. Finally, K.J. Harrison & Partners Inc raised its stake in AbbVie by 0.6% in the first quarter. K.J. Harrison & Partners Inc now owns 5,031 shares of the company’s stock worth $328,000 after buying an additional 31 shares during the last quarter. 68.04% of the stock is currently owned by institutional investors and hedge funds.

Shares of AbbVie Inc. (ABBV) opened at 74.63 on Friday. AbbVie Inc. has a 52 week low of $55.06 and a 52 week high of $75.04. The stock has a market capitalization of $118.78 billion, a P/E ratio of 19.34 and a beta of 1.51. The firm’s 50-day moving average price is $71.21 and its 200 day moving average price is $65.76.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Thursday, April 27th. The company reported $1.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.02. The business had revenue of $6.54 billion for the quarter, compared to the consensus estimate of $6.49 billion. AbbVie had a return on equity of 148.83% and a net margin of 24.07%. The business’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.15 earnings per share. Analysts expect that AbbVie Inc. will post $5.53 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, August 15th. Stockholders of record on Friday, July 14th will be given a dividend of $0.64 per share. This represents a $2.56 dividend on an annualized basis and a dividend yield of 3.43%. The ex-dividend date of this dividend is Wednesday, July 12th. AbbVie’s payout ratio is presently 66.32%.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/07/23/sfmg-llc-invests-285000-in-abbvie-inc-abbv.html.

A number of analysts recently issued reports on ABBV shares. Vetr upgraded AbbVie from a “buy” rating to a “strong-buy” rating and set a $74.38 price objective on the stock in a research note on Monday, May 8th. BMO Capital Markets set a $63.00 price objective on AbbVie and gave the company a “hold” rating in a research note on Thursday, April 27th. Credit Suisse Group reiterated a “hold” rating and set a $65.00 price objective on shares of AbbVie in a research note on Wednesday, June 7th. Deutsche Bank AG boosted their price objective on AbbVie from $64.00 to $65.00 and gave the company a “hold” rating in a research note on Friday, April 28th. Finally, Jefferies Group LLC reiterated a “buy” rating on shares of AbbVie in a research note on Friday, May 26th. Nine research analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $74.52.

In other news, CFO William J. Chase sold 38,300 shares of the company’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $65.35, for a total transaction of $2,502,905.00. Following the transaction, the chief financial officer now directly owns 209,043 shares of the company’s stock, valued at $13,660,960.05. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Carlos Alban sold 43,000 shares of the company’s stock in a transaction on Thursday, May 4th. The stock was sold at an average price of $67.00, for a total value of $2,881,000.00. Following the transaction, the executive vice president now directly owns 114,745 shares in the company, valued at $7,687,915. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 278,135 shares of company stock worth $18,841,085. Insiders own 0.23% of the company’s stock.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.